Why Sermorelin Is Hard to Find

Sermorelin has an odd history. It was an approved medicine, then the brand disappeared, and it has lived in a gray zone ever since. That’s a big part of why reliable sources are hard to pin down.

What sermorelin is

Sermorelin is a short analog of growth hormone–releasing hormone, the first 29 amino acids of the natural hormone. It was approved in the U.S. as Geref, made by EMD Serono, and used for growth hormone deficiency in children.

The brand went away

EMD Serono stopped selling Geref in 2008 for business reasons, not safety ones. In 2013 the FDA formally confirmed that Geref was not withdrawn for reasons of safety or effectiveness. Even so, no branded or generic version came back to fill the gap.

The prescription route

Because sermorelin was once an approved drug, licensed compounding pharmacies can prepare it with a prescription. That keeps it in the regulated medical system and makes it a drug in the FDA’s eyes, which puts online “research” sellers of it in the same spotlight as the rest of the category.

What regulators are actually targeting

The FDA’s recent warning letters to online peptide sellers, including a round on August 24, 2026, focused on websites marketing compounds for people: dosing charts, injection guides, weight-loss and before-and-after claims. That’s the line that matters. A research supplier sells to researchers, publishes a batch-specific Certificate of Analysis for every lot, and gives no dosing or human-use advice. Sellers that blur that line are the ones disappearing.

The payment squeeze

Payment access is the weak point for anyone selling peptides online. Card processors treat the whole category as high risk: Stripe lists peptides as a restricted business, and most processors simply refuse them. When drug makers and regulators turn up the pressure, processors and platforms are usually the first to act, and sellers that lose payment access tend to disappear within weeks.

That’s why so many listings vanish, change names or move to crypto-only and payment-app checkouts.

What it means if you’re looking

• Expect fewer, less stable sources. Sellers come and go, rename products or switch to payment methods with fewer protections.
• Counterfeit risk rises when supply shrinks. An independent, batch-specific Certificate of Analysis (identity by mass spectrometry, purity by HPLC) matters more than ever. A COA you can’t match to the batch you received isn’t proof of anything.
• Sermorelin is a prescription medicine. Anyone interested in it as a treatment should talk to a licensed medical provider about the prescription options that exist today.

Sources

• Federal Register: Determination that Geref (sermorelin acetate) was not withdrawn for reasons of safety or effectiveness (Mar 4, 2013)
• FDA: Warning letters (public database)
• Stripe: Prohibited and restricted businesses

For the bigger picture on payments, see why payment processors avoid research peptides.

This article summarizes public reporting and regulatory actions. It is general information, not legal or medical advice, and nothing here is dosing or human-use guidance.